Use of alpelisib in the treatment of hormone receptor positive metastatic breast cancer: An institutional experience.

e15216Background: Mutations in PI3K pathway is a known mechanism of resistance to endocrine therapy in breast cancer. Alpelisib is an alpha-specific PI3K inhibitor. Alpelisib with Fulvestrant is ap...